Last updated on May 2018

A Phase 3 clinical study for patients with follicular lymphoma


Brief description of study

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Clinical Study Identifier: NCT02213263

Contact Investigators or Research Sites near you

Start Over

The Oncology Institute of Hope and Innovation
Lynwood, CA United States
0.72miles

The Oncology Institute of Hope and Innovation
Downey, CA United States
4.7miles

The Oncology Institute of Hope and Innovation
Long Beach, CA United States
4.95miles

The Oncology Institute of Hope and Innovation
Montebello, CA United States
8.05miles

Good Samaritan Imaging
Los Angeles, CA United States
9.24miles

Los Angeles Hematology Oncology Medical Group
Los Angeles, CA United States
9.24miles